Bulls vs Bears
Click to unlock major analysts' bullish and bearish positions by joining Benzinga Edge.
Click to unlock major analysts' bullish and bearish positions by joining Benzinga Edge.
Ligand Pharmaceuticals Inc has a consensus price target of $135 based on the ratings of 8 analysts. The high is $160 issued by Barclays on December 16, 2024. The low is $90 issued by Roth Capital on December 23, 2022. The 3 most-recent analyst ratings were released by Benchmark, Barclays, and RBC Capital on December 23, 2024, December 16, 2024, and December 11, 2024, respectively. With an average price target of $146 between Benchmark, Barclays, and RBC Capital, there's an implied 28.30% upside for Ligand Pharmaceuticals Inc from these most-recent analyst ratings.
1calculated from analyst ratings
The latest price target for Ligand Pharmaceuticals (NASDAQ:LGND) was reported by Benchmark on December 23, 2024. The analyst firm set a price target for $135.00 expecting LGND to rise to within 12 months (a possible 18.63% upside). 25 analyst firms have reported ratings in the last year.
The latest analyst rating for Ligand Pharmaceuticals (NASDAQ:LGND) was provided by Benchmark, and Ligand Pharmaceuticals reiterated their buy rating.
There is no last upgrade for Ligand Pharmaceuticals
There is no last downgrade for Ligand Pharmaceuticals.
Analysts arrive at stock ratings after doing extensive research, which includes going through public financial statements, talking to executives and customers of Ligand Pharmaceuticals, and listening in to earnings conference calls. Most analysts do this every three months, so you should get 4 ratings per company per firm each year. The last rating for Ligand Pharmaceuticals was filed on December 23, 2024 so you should expect the next rating to be made available sometime around December 23, 2025.
While ratings are subjective and will change, the latest Ligand Pharmaceuticals (LGND) rating was a reiterated with a price target of $135.00 to $135.00. The current price Ligand Pharmaceuticals (LGND) is trading at is $113.80, which is out of the analyst’s predicted range.
Browse analyst ratings and price targets on all stocks.